Related Blog Posts from the Wikinvest Wire

Bristol-Myers Squibb Company (BMY)   Subscribe to Bristol-Myers Squibb Company (BMY) content from the Wikinvest Wire
 » Back to Bristol-Myers S… (NYSE:BMY) Stock Page

  

10/24/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Third Qua... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported strong financial results for the third quarter of 2014, adjusted 2014 GAAP guidance and confirmed 2014 non-GAAP guidance. The Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $89.34B, began trading this morning at $52.65.   A quick look at [...]

10/13/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb, Pharmacyclics and... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company , Pharmacyclics, Inc. , and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® in combination with IMBRUVICA® , an oral Bruton's tyrosine kinase [...]

9/26/14Stock Update (NYSE:BMY): Bristol immunotherapy gets 6-month U.S. FDA review for melanoma (Jutia Group)

[Reuters - UK Focus] - The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $84.72B, opened at $51.78. [...]

9/11/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Bank... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Bank of America Merrill Lynch Global Health Care Conference on Thursday, September 18, 2014, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 9:45 a.m. Read more on this. Bristol-Myers Squibb [...]

9/2/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Mo... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will take part in the Morgan Stanley 2014 Global Health Care Conference on Monday, September 8, 2014, in New York. Giovanni Caforio, chief operating officer, will answer questions about the company at 2 p.m. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $83.86B, started the [...]

8/27/14Market Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Daklinza (daclata... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza , a potent, pan-genotypic NS5A replication complex inhibitor , for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults. Read more on this. [...]

8/21/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – U.S. FDA Approves Eliquis (apixaban) fo... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced the U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. Read more on this. Bristol-Myers [...]

8/20/14Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixab... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. announced today that they will present 14 abstracts at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $83.04B, opened at [...]

8/7/14Bristol-Myers Squibb Company (NYSE:BMY) | Leica Biosystems and Bristol-Myers Squibb Enter Into a ... (Jutia Group)

[PR Newswire] - Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics Leica Biosystems will develop fully automated tissue-based companion diagnostic tests to run on the BOND™ automated advanced staining systems Leica Biosystems, today announced an agreement with Bristol-Myers Squibb Company (BMY) to collaborate on [...]

8/4/14Bristol-Myers Squibb Company (NYSE:BMY) – Allied Minds and Bristol-Myers Squibb Form New Enterp... (Jutia Group)

[at noodls] - Allied-Bristol Life Sciences LLC to identify and speed development of promising science and technologies Unique collaboration focused on transforming early-stage academic innovation to therapeutic candidates ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $82.71B, opened this morning at $49.82.   A quick look at [...]

7/29/14Company Update (NYSE:BMY): European Commission Approves Eliquis (apixaban) for the Treatment of D... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $83.57B, started the session at [...]

7/24/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Second Quarter 2014 Fina... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company’s key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; [...]

7/1/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Announce Resul... (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the second quarter on Thursday, July 24, 2014. During a conference call at 10:30 a.m. EDT on July 24, company ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $79.63B, opened at $48.48.   [...]

6/27/14Bristol-Myers Squibb Company (NYSE:BMY) – Eliquis® (apixaban) Receives CHMP Positive Opinion f... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that Eliquis be granted marketing authorization for the treatment of DVT and PE , and the prevention of recurrent DVT and PE, in [...]

6/17/14Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend (Jutia Group)

[Business Wire] - The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of thirty-six cents per share on the $.10 par value Common Stock of the corporation. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $78.65B, started the session at $47.23.   Today’s [...]

6/3/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Syngene Inter... (Jutia Group)

[Business Wire] - PRINCETON, N.J. & BANGALORE, India--(BUSINESSWIRE)-- Bristol-Myers Squibb (NYSE:BMY - News) and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities [...]

5/19/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and AbbVie Receive U.S. FDA Brea... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies. Read more [...]

5/16/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Hold Investor T... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will host a teleconference on Monday, June 2, 2014, at 8 a.m. EDT to review data presented at the Annual Meeting of the American Society of Clinical Oncology in Chicago. Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $80.85B, started trading [...]

5/14/14Market Update (NYSE:BMY): Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial C... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Celldex Therapeutics, Inc. announced today that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study. Read more on this. [...]

5/12/14Stock Update (NYSE:BMY): Bristol-Myers Squibb to Present at UBS Global Healthcare Conference (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the UBS Global Health Care Conference on Monday, May 19, 2014, in New York. Giovanni Caforio, executive vice president and chief commercial officer, will make a formal presentation about the company at 3 p.m. Read more on this. Bristol-Myers Squibb Company (BMY), with a [...]

5/6/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces Retirem... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company, effect Read more on this. Bristol-Myers Squibb Company (BMY), valued at $84.42B, opened this morning at $49.96.   Looking at today's market, BMY one day [...]

4/29/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports First Quarter 2014 Finan... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported financial results for the first quarter of 2014 and adjusted GAAP and non-GAAP guidance for 2014. The first quarter was highlighted by the achievement of important regulatory milestones for Eliquis, daclatasvir/asunaprevir and the diabetes franchise. Read more on this. Bristol-Myers Squibb Company (BMY), with a [...]

4/24/14Company Update (NYSE:BMY): Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that it has been ranked No. 1 on Corporate Responsibility magazine’s 2014 list of the 100 Best Corporate Citizens, a leading Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $83.39B, opened this morning at $51.02.   Shares [...]

4/22/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Samsung BioLog... (Jutia Group)

[Business Wire] - NEW YORK & SEOUL, South Korea--(BUSINESSWIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics today announced the companies will increase the scope of their existing manufacturing agreement ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $84.15B, started the session at $50.47.   [...]

4/14/14Company Update (NYSE:BMY): Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fi... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today the submission of a new drug application on April 4, 2014 to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz®, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of [...]

4/7/14Market Update (NYSE:BMY): Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that they have submitted new drug applications with the U.S. Food and Drug Administration for the investigational products daclatasvir , an NS5A replication complex inhibitor, and asunaprevir , a NS3 protease inhibitor. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $83.29B, started the [...]

3/27/14Company Update (NYSE:BMY): In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis compared to warfarin according to blood pressure control.1 The results showed that poor [...]

3/17/14Market Update (NYSE:BMY): Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agr... (Jutia Group)

[at noodls] - "This strategic alliance is evidence that our protein discovery platform is ideally suited to identify novel immune checkpoint targets for the development of next generation immuno-oncology therapeutics." ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $89.90B, opened this morning at $54.48.   Looking at [...]

3/14/14Stock Update (NYSE:BMY): U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application ( Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $89.11B, started the session at $54.15.   Looking at the stock, its [...]

3/5/14Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Presents Promisin... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound, BMS-663068, when compared to a boosted protease inhibitor, Reyataz® with ritonavir. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $93.91B, started the session at $56.22.   Looking [...]

3/4/14Company Update (NYSE:BMY): Bristol-Myers Squibb’s Management Presents at Cowen Health Care Conf... (Jutia Group)

[Seeking Alpha] - Well, good morning and welcome to the Bristol-Myers Squibb session of Cowen’s 34th Annual Healthcare Conference. We are very pleased to have Bristol with us again this year. Representing the company is Dr. Brian Daniels, who is Senior Vice President, Global Development and Medical Affairs. Bristol has been and continues to [...]

2/25/14Bristol-Myers Squibb Company (NYSE:BMY) | FDA approves Bristol-Myers drug for rare body fat disorder (Jutia Group)

[Reuters] - Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The drug has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital or acquired generalized lipodystrophy. Generalized lipodystrophy [...]

2/24/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Receives U.S. FDA ... (Jutia Group)

[at noodls] - FDA grants Designation request for investigational daclatasvir (DCV) and asunaprevir (ASV) combination therapy for treatment of genotype 1b chronic hepatitis C (HCV) infection Marks second Breakthrough ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $90.19B, opened this morning at $54.24.   Looking at the [...]

2/21/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – In a Subanalysis, Eliquis® (apixaban) ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular [...]

2/20/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Cowen and Company ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Cowen and Company 34th Annual Global Health Care Conference on Tuesday, March 4, 2014, in Boston. Brian Daniels, senior vice president, Global Development and Medical Affairs, will make a formal presentation about the company at 10 a.m. Read more on this. Bristol-Myers Squibb [...]

2/14/14Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at Ci... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will present at the Citi 2014 Global Health Care Conference on Monday, February 24, 2014, in New York. Francis Cuss, executive vice president and chief scientific officer, will make a formal presentation about the company at 2:40 p.m. Read more on this. Bristol-Myers Squibb Company (BMY), with [...]

2/5/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Leerink Swann Gl... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company will take part in the Leerink Swann Global Health Care Conference on Wednesday, February 12, 2014, in New York. Charles Bancroft, executive vice president and chief financial officer, will answer questions about the company at 10:15 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), currently valued [...]

1/27/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – One Factor Driving Bristol-Myers Squibb... (Jutia Group)

[at TheStreet] - Bristol-Myers Squibb (BMY) falls after concerns about the rate at which the company is developing a new combination of cancer treatment drugs. The New York City-based company announced Friday that it was ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $81.87B, opened at [...]

1/24/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Fourth Quarter and Full ... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company’s announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. Read more on this. Bristol-Myers [...]

1/22/14Company Update (NYSE:BMY): High Stakes Intrigue In Hep C: Bristol-Myers Vs. Gilead (Jutia Group)

[at Seeking Alpha] - Gilead's ( GILD ) reluctance to marry its Hep C drug Sovaldi with Bristol-Myers Squibb's ( BMY ) daclatasvir forced Bristol to take evasive action. Bristol applied to the European Union for approval of ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $90.25B, opened at $54.74. [...]

1/16/14Bristol-Myers Squibb Company (NYSE:BMY) ~ AstraZeneca and Bristol-Myers Squibb Diabetes Alliance ... (Jutia Group)

[Business Wire] - AstraZeneca and Bristol-Myers Squibb Company today announced that the companies’ U.S. Diabetes Alliance is providing a three-year grant to the American Diabetes Association’s Pathway to Stop Diabetes program. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $89.93B, opened this morning at $54.25.   Looking at [...]

1/14/14Bristol-Myers Squibb Company (NYSE:BMY) | Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill (Jutia Group)

[at Bloomberg] - Bristol-Myers Squibb Co. will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc.’s approved pill.... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $91.79B, opened at $55.49.   Looking at [...]

1/10/14Bristol-Myers Squibb Company (NYSE:BMY) ~ How Will the Top Line Change for Repligen in 2014? (Jutia Group)

[at Motley Fool] - Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors? Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $91.97B, started the session at $55.82.   During today's session, BMY [...]

1/9/14Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Forxiga Approval Should Be Boon Fo... (Jutia Group)

[at Seeking Alpha] - Both AstraZeneca PLC ( AZN ) and the Bristol-Myers Squibb Co. ( BMY ) are anticipated beneficiaries of the U.S. Food and Drug Administration announcement Wednesday that it has approved Forxiga (dapagliflozin) ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current value of $90.68B, opened at [...]

1/8/14Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Daclatasvir Marketing Authorization A... (Jutia Group)

[at noodls] - Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4 Submission includes EU's first all-oral and ribavirin-free ... Read more on this. Bristol-Myers Squibb Company (BMY), valued at $87.33B, opened this morning at $52.42.   [...]

1/6/14Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Present at... (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014, in San Francisco. Lamberto Andreotti, chief executive ... Read more on this. Bristol-Myers Squibb Company (BMY), with a current market cap of $86.76B, started the session at $53.07.   [...]

1/3/14Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb to Take Part in Goldman Sachs He... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company announced today that it will take part in Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, January 7, 2014, in Boston. Lamberto Andreotti, chief executive officer, will answer questions about the company at 10:15 a.m. Read more on this. Bristol-Myers Squibb Company (BMY), valued at $87.09B, began [...]

1/2/14Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Vs. Roche In The B... (Jutia Group)

[at Seeking Alpha] - In January, Bristol-Myers Squibb ( BMY ) , will start a Phase 2 study in patients with glioblastoma. The trial is part of a series in which Bristol combines its experimental drug, nivolumab, with the approved ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.04B, [...]

12/27/13Bristol-Myers Squibb Company (NYSE:BMY) | [$$] Bristol-Myers’ AstraZeneca Deal Is a Win (Jutia Group)

[at Barrons.com] - Hilliard Lyons Bristol-Myers Squibb agreed to sell its part of a diabetes-care collaboration to its partner, AstraZeneca. The two companies have collaborated on the development and commercialization of ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.58B, started the session at $53.66.   [...]

12/20/13Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Should Dividend Growth Investors Give U... (Jutia Group)

[at Seeking Alpha] - Bristol-Myers Squibb ( BMY ) announced its annual dividend increase on Thursday, December 19th. Here are some quick recaps from the announcement: The new quarterly dividend is 36 cents per share.This is ... Read more on this. Bristol-Myers Squibb Company (BMY), currently valued at $87.88B, began trading this morning [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki